Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review

Expert Review of Pharmacoeconomics & Outcomes Research
Slobodan M JankovićMarina Kostić

Abstract

Evolocumab is fully human monoclonal antibody which binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), and prevents its blocking effect on recycling of liver low-density lipoprotein (LDL) receptors. Areas covered: The aim of this review is to assess efficacy, safety, and cost-effectiveness of evolocumab in adult patients with high cardiovascular risk. Major research databases MEDLINE, EBSCO, and CENTRAL were systematically searched for relevant study reports. Expert commentary: Even when given in full doses, statins augmented with ezetimibe and cholesterol-binding resins could not reduce cholesterol baseline level for more than 66%, while evolocumab reduces cholesterol level for 75% or even more. Up to now, evolocumab showed good safety profile, and patents tolerate it very well. The abovementioned advantages of evolocumab made it almost ideal drug for hypercholesterolemia, and probably in the future the best drug for secondary prevention of major cardiovascular events. Evolocumab is borderline cost-effective for the treatment of patients with high cardiovascular risk in European countries, while in the U.S.A. it is under debate where the underlying assumption (risk of cardiovascular disease events) determine the t...Continue Reading

References

Dec 21, 2000·Journal of Clinical Pharmacy and Therapeutics·D N KiortsisG Turpin
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Aug 27, 2010·The Permanente Journal·Vicki FungRuth Shaber
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Nov 25, 2011·The American Journal of Cardiology·Masa-Aki KawashiriMasakazu Yamagishi
Mar 23, 2012·The New England Journal of Medicine·Evan A SteinGary D Swergold
Apr 1, 2014·The New England Journal of Medicine·Dirk J BlomUNKNOWN DESCARTES Investigators
Apr 3, 2014·Journal of the American College of Cardiology·Michael J KorenUNKNOWN MENDEL-2 Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc S SabatineUNKNOWN Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators
Apr 1, 2015·Expert Review of Cardiovascular Therapy·Gisle LangsletScott M Wasserman
Jun 26, 2015·Drug Design, Development and Therapy·Arrigo F G CiceroClaudio Borghi
Sep 2, 2015·Drugs·Anthony Markham
Oct 28, 2015·Circulation·Gregory A RothChristopher J L Murray
Nov 9, 2015·The American Journal of Cardiology·Arihiro KiyosueAtsushi Hirayama
Dec 9, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Gillian M Keating
Mar 20, 2016·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Josep Redon
May 28, 2016·Journal of Managed Care & Specialty Pharmacy·Marian McDonaghSergio Fazio
Jun 1, 2016·Cardiovascular Drugs and Therapy·Robert S RosensonMichael Miller
Jul 28, 2016·Drugs·Stephan KrähenbühlArnold von Eckardstein
Aug 2, 2016·British Journal of Clinical Pharmacology·Ioanna Gouni-BertholdWinfried März
Aug 18, 2016·JAMA : the Journal of the American Medical Association·Dhruv S KaziKirsten Bibbins-Domingo
Aug 29, 2016·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Enrico Agabiti Rosei, Massimo Salvetti
Oct 30, 2016·Australian Prescriber
Nov 11, 2016·Cardiovascular Drugs and Therapy·Chayakrit KrittanawongTao Sun
Nov 16, 2016·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Apr 4, 2017·Clinical Therapeutics·Guillermo VillaBen van Hout
Apr 27, 2017·European Heart Journal. Cardiovascular Pharmacotherapy·Max Korman, Torbjørn Wisløff

❮ Previous
Next ❯

Citations

May 28, 2021·Frontiers in Cardiovascular Medicine·Dara VakiliDeepak L Bhatt

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.